JP2019529541A - 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 - Google Patents

高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 Download PDF

Info

Publication number
JP2019529541A
JP2019529541A JP2019535191A JP2019535191A JP2019529541A JP 2019529541 A JP2019529541 A JP 2019529541A JP 2019535191 A JP2019535191 A JP 2019535191A JP 2019535191 A JP2019535191 A JP 2019535191A JP 2019529541 A JP2019529541 A JP 2019529541A
Authority
JP
Japan
Prior art keywords
dosage form
subject
agent
influenza
additional therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019535191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529541A5 (enExample
Inventor
パリッシュ ハイド−デルイスシャー，ロビン
パリッシュ ハイド−デルイスシャー，ロビン
ハーラン ハイド−デルイスシャー，ナンシー
ハーラン ハイド−デルイスシャー，ナンシー
クリスティン ハイド−デルイスシャー，エリシア
クリスティン ハイド−デルイスシャー，エリシア
Original Assignee
エマーゴ セラピューティクス，インク．
エマーゴ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エマーゴ セラピューティクス，インク．, エマーゴ セラピューティクス，インク． filed Critical エマーゴ セラピューティクス，インク．
Publication of JP2019529541A publication Critical patent/JP2019529541A/ja
Publication of JP2019529541A5 publication Critical patent/JP2019529541A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2019535191A 2016-09-08 2017-09-07 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 Pending JP2019529541A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662385021P 2016-09-08 2016-09-08
US62/385,021 2016-09-08
PCT/US2017/050409 WO2018048989A1 (en) 2016-09-08 2017-09-07 Mast cell stabilizers for treatment of hypercytokinemia and viral infection

Publications (2)

Publication Number Publication Date
JP2019529541A true JP2019529541A (ja) 2019-10-17
JP2019529541A5 JP2019529541A5 (enExample) 2020-10-08

Family

ID=61281984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535191A Pending JP2019529541A (ja) 2016-09-08 2017-09-07 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤

Country Status (15)

Country Link
US (5) US10501527B2 (enExample)
EP (1) EP3509596B1 (enExample)
JP (1) JP2019529541A (enExample)
KR (1) KR20190073365A (enExample)
CN (1) CN109952101A (enExample)
AU (2) AU2017325010A1 (enExample)
BR (1) BR112019004496A2 (enExample)
CA (1) CA3036230A1 (enExample)
ES (1) ES2988617T3 (enExample)
IL (1) IL265208A (enExample)
MX (1) MX389999B (enExample)
MY (1) MY204310A (enExample)
PH (1) PH12019500513A1 (enExample)
RU (1) RU2760682C2 (enExample)
WO (1) WO2018048989A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
CA3036230A1 (en) * 2016-09-08 2018-03-15 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of hypercytokinemia and viral infection
WO2018075574A1 (en) 2016-10-18 2018-04-26 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of chronic inflammatory conditions
AU2019336698A1 (en) * 2018-09-05 2021-03-25 Aztherapies, Inc. Methods of treating cytokine release syndrome
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
US20200268734A1 (en) * 2019-02-22 2020-08-27 Bridge Pharma, Inc. Methods of treatment of respiratory disorders
US10959992B2 (en) 2019-02-22 2021-03-30 Bridge Pharma Inc. Methods of treatment of asthma and COPD
WO2021178395A1 (en) * 2020-03-06 2021-09-10 Figene, Llc Fibroblast and tlr activated fibroblast treatment of viral induced acute respiratory distress syndrome
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US20230000852A1 (en) * 2021-06-29 2023-01-05 Bridge Pharma, Inc. Treatment of Dermal Cytokine Storm Syndromes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015020878A1 (en) * 2013-08-06 2015-02-12 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through histamine h-4 receptors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
WO1998035677A1 (en) 1997-02-18 1998-08-20 Bridge Pharma, Inc. Non-sedating histamine antagonist compounds, compositions and methods of use thereof
JP2001519789A (ja) 1997-04-03 2001-10-23 ブリッジ ファーマ，インコーポレーテッド ベンゾシクロヘプタチオフェン化合物
EP1014979A4 (en) 1997-06-09 2003-08-20 Bridge Pharma Inc CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE
CA2283603A1 (en) 1998-10-01 2000-04-01 Paul W. Behnke Forced closed-loop cooling for a submersible pump motor
HUP0202671A3 (en) 1999-09-13 2005-01-28 Bridge Pharma Inc Sarasota Optically active isomers of ketotifen and therapeutically active metabolites thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20030118670A1 (en) * 2001-07-11 2003-06-26 Smith C. Steven Novel composition and method for altering allergenic protein in the environment
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
US20060084695A1 (en) 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
WO2007084253A2 (en) 2005-11-28 2007-07-26 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
SG177934A1 (en) 2006-09-29 2012-02-28 Johnson & Johnson Vision Care Methods and ophthalmic devices used in the treatment of ocular allergies
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
WO2009050203A1 (en) 2007-10-15 2009-04-23 Revolymer Limited Solvent-free synthesis of amphiphilic polymeric material
EP2234329A4 (en) 2007-12-24 2012-11-21 Zte Corp METHOD AND SYSTEM FOR PROTECTING THE SHARED CHANNEL IN THE OPTICAL TRANSMISSION SYSTEM
BRPI0822221A2 (pt) * 2008-01-04 2015-06-23 Alcon Pharmaceuticals Ltd Composições aquosas e estáveis de ciclosporina
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
US8741930B2 (en) 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス， インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
US20110294897A1 (en) 2009-12-02 2011-12-01 Bridge Pharma, Inc. Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
HK1198328A1 (zh) 2011-07-13 2015-04-02 Abbvie Inc. 使用抗il-13抗體治療哮喘的方法和組合物
WO2014040112A1 (en) 2012-09-17 2014-03-20 Guina Research & Development Pty Ltd Electromagnetic turbine
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US20140120121A1 (en) 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US9347325B2 (en) 2012-10-31 2016-05-24 Solar Turbines Incorporated Damper for a turbine rotor assembly
JP6084473B2 (ja) 2013-02-01 2017-02-22 日立オートモティブシステムズ株式会社 複合センサ
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
CA2976369A1 (en) 2015-02-13 2016-08-18 Yale University Biaryltriazole inhibitors of macrophage migration inhibitory factor
US10293352B2 (en) 2015-02-13 2019-05-21 Kärcher North America, Inc. Hand held fluid dispensing apparatus
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
US9694003B2 (en) 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
CA3036230A1 (en) 2016-09-08 2018-03-15 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of hypercytokinemia and viral infection
WO2018075574A1 (en) 2016-10-18 2018-04-26 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of chronic inflammatory conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015020878A1 (en) * 2013-08-06 2015-02-12 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through histamine h-4 receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HU, Y. ET AL.: "Mast cell-induced lung injury in mice infected with H5N1 influenza virus", JOURNAL OF VIROLOGY, vol. 86, no. 6, JPN6021028840, 2012, pages 3347 - 3356, ISSN: 0004819701 *

Also Published As

Publication number Publication date
MX389999B (es) 2025-03-11
US11072648B2 (en) 2021-07-27
PH12019500513A1 (en) 2019-05-27
EP3509596B1 (en) 2024-07-03
US20180072796A1 (en) 2018-03-15
CA3036230A1 (en) 2018-03-15
RU2760682C2 (ru) 2021-11-29
EP3509596A4 (en) 2020-05-06
BR112019004496A2 (pt) 2019-05-28
US10160796B2 (en) 2018-12-25
MX2019002781A (es) 2019-09-04
US10494420B2 (en) 2019-12-03
US20200055926A1 (en) 2020-02-20
US10787502B2 (en) 2020-09-29
RU2019110150A (ru) 2020-10-08
AU2023204000A1 (en) 2023-07-13
RU2019110150A3 (enExample) 2020-12-18
EP3509596A1 (en) 2019-07-17
KR20190073365A (ko) 2019-06-26
AU2017325010A1 (en) 2019-03-28
IL265208A (en) 2019-05-30
WO2018048989A1 (en) 2018-03-15
ES2988617T3 (es) 2024-11-21
US20190085057A1 (en) 2019-03-21
EP3509596C0 (en) 2024-07-03
US20200055927A1 (en) 2020-02-20
CN109952101A (zh) 2019-06-28
US10501527B2 (en) 2019-12-10
MY204310A (en) 2024-08-22
US20180066039A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US10787502B2 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US20080255224A1 (en) Pharmacological treatment of psoriasis
JP2016512833A (ja) ウイルス感染症の治療薬としてのベラプロスト異性体
JP2020534362A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
AU2018206907A1 (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
EP2969001A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
US20200069716A1 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
JP6454436B1 (ja) ペマフィブラートを含有する医薬
JP2019515927A (ja) 感染症の処置のための方法
HK40011695A (en) Norketotifen for treatment of hypercytokinemia and viral infections
HK40011695B (en) Norketotifen for treatment of hypercytokinemia and viral infections
JP2019533018A (ja) 慢性炎症状態の処置の為の肥満細胞安定剤
AU2021252229A1 (en) Endoxifen for the treatment of bipolar I disorder
WO2005063253A1 (ja) アレルギー症状治療用医薬組成物
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
JP2019001830A (ja) 医薬
AU2023397177A1 (en) Solid dosage form of a small molecule antiviral and uses thereof
Brewer et al. Intranasal nystatin therapy in patients with chronic illness associated with mold and mycotoxins
WO2022145407A1 (ja) Ｄｐ１アンタゴニストおよびノイラミニダーゼ阻害剤からなるウイルス性気道感染症治療用医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220706

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221104

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20221115

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221215

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240925